Category Research

Scipher Medicine Unveils AI Platform to Predict Clinical Trial Failure

Scipher Medicine Launches ClinicalTrialRank.com: AI-Powered Platform to Predict Clinical Trial Failure and Transform Drug Development Strategy Scipher Medicine, a pioneering company in precision immunology and network medicine, has officially announced the public launch of ClinicalTrialRank.com, a first-of-its-kind artificial intelligence (AI)…

Read MoreScipher Medicine Unveils AI Platform to Predict Clinical Trial Failure
Rocket

Rocket Pharmaceuticals Cleared to Resume Phase 2 RP-A501 Study in Danon Disease

Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Pivotal Phase 2 Trial of RP-A501 in Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a diverse pipeline of genetic therapies for rare and devastating disorders,…

Read MoreRocket Pharmaceuticals Cleared to Resume Phase 2 RP-A501 Study in Danon Disease
MedImpact

MedImpact Launches Low-Cost Ustekinumab-aekn Biosimilar Nationwide

MedImpact Unveils Affordable Access to Unbranded Ustekinumab-aekn Biosimilar, Reshaping Specialty Pharmacy Market MedImpact Holdings Inc., the nation’s largest independent pharmacy benefit and healthcare solutions provider, announced a major step toward addressing escalating specialty drug costs with the launch of access…

Read MoreMedImpact Launches Low-Cost Ustekinumab-aekn Biosimilar Nationwide

jCyte Begins Patient Treatment in Phase JC02-88 Clinical Trial for Retinitis Pigmentosa

jCyte Marks Major Milestone with First Patients Treated in JC02-88 Clinical Trial Evaluating jCell for Retinitis Pigmentosa jCyte, Inc., a clinical-stage biotechnology company pioneering cell-based therapies for retinal diseases, announced a pivotal advancement in its development program: the enrollment and…

Read MorejCyte Begins Patient Treatment in Phase JC02-88 Clinical Trial for Retinitis Pigmentosa

RenovoRx Posts Q2 2025 Growth, Phase III Trial Cleared to Continue

RenovoRx Reports Strong Q2 2025 Revenue Growth and Receives Positive Independent Committee Recommendation to Continue Phase III TIGeR-PaC Trial RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage life sciences company pioneering targeted oncology drug delivery therapies, announced financial results for the second…

Read MoreRenovoRx Posts Q2 2025 Growth, Phase III Trial Cleared to Continue

ScaleReady Awards G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory

ScaleReady Awards $300,000 G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory to Advance Modular CAR T-Cell Manufacturing ScaleReady, a joint venture formed by Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, today announced that the Translational Sciences Laboratory at the Gates…

Read MoreScaleReady Awards G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory

SAPPHIRE Trial: Apitegromab Boosts Motor Function in SMA, Published in The Lancet Neurology

Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neuromuscular diseases, announced today that…

Read MoreSAPPHIRE Trial: Apitegromab Boosts Motor Function in SMA, Published in The Lancet Neurology

Pilatus, Roche Partner on First-in-Human PLT012 Liver Cancer Trial

Pilatus Biosciences Launches Clinical Trial Collaboration with Roche to Advance First-in-Human Evaluation of PLT012 in Liver Cancer Pilatus Biosciences, Inc., a biotechnology company focused on developing innovative metabolic checkpoint immunotherapies for difficult-to-treat liver and gastrointestinal cancers, announced today a new…

Read MorePilatus, Roche Partner on First-in-Human PLT012 Liver Cancer Trial

Response Pharma Reports Positive Phase 2 Results for RDX-002 in Post-GLP-1 Care

Response Pharmaceuticals Announces Positive Phase 2 Results for RDX-002 in Post-GLP-1 Obesity Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation therapies for weight management and metabolic health, has reported encouraging top-line results from a double-blind, placebo-controlled…

Read MoreResponse Pharma Reports Positive Phase 2 Results for RDX-002 in Post-GLP-1 Care

Bionova Scientific® Launches New Plasmid DNA Facility in Texas to Meet Rising Biopharma Demand

Bionova Scientific® Inaugurates Advanced Plasmid DNA Production Facility in Texas to Support Surging Global Demand for Cell and Gene Therapy Materials Bionova Scientific®, a full-service biologics contract development and manufacturing organization (CDMO) and a wholly owned subsidiary of the global…

Read MoreBionova Scientific® Launches New Plasmid DNA Facility in Texas to Meet Rising Biopharma Demand

Newron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for diseases affecting the central and…

Read MoreNewron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia

NorthStar Medical Technologies Names Jon Coulter as Non-Executive Chairman

NorthStar Medical Technologies Appoints Jon Coulter as Non-Executive Chairman, Marking a Key Step in Leadership Succession for Continued Growth in the Radiopharmaceutical Sector NorthStar Medical Technologies, LLC, a recognized global innovator in the development, production, and commercialization of advanced radiopharmaceuticals…

Read MoreNorthStar Medical Technologies Names Jon Coulter as Non-Executive Chairman